Minerva Neurosciences, Inc. (NERV)
NasdaqCM
Price as at 30 Sept 2026, 21:45 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Minerva Neurosciences, Inc. trades at $3.35. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
4 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Farallon Capital, FARALLON CAPITAL MANAGEMENT, L.L.C.$13.13M · 0.1% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$2.96M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$406.8K · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$142.5K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own NERV?
4 of the institutions we track reported a position in NERV in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its NERV data?
Fundamentals for NERV come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:45 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for NERV, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.